Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.
Histol Histopathol. 2010 Aug;25(8):963-74. doi: 10.14670/HH-25.963.
The most suitable immunohistochemical criterion to identify basal-like breast carcinomas (BLBC), a molecular subgroup of breast cancer associated with poor prognosis, is the triple negative phenotype along with CK5 and/or EGFR immunoreactivity. However, several putative basal markers have been suggested as alternatives to identify BLBC with more accuracy.
The expression of CK5, EGFR, P-cadherin, CK14, Vimentin and p63 were evaluated in 462 invasive breast carcinomas to determine their sensitivity and specificity for BLBC identification.
P-cadherin and CK5 showed higher sensitivity values, while EGFR, Vimentin and CK14 were the most specific markers. The combination of CK5 with P-cadherin, Vimentin or CK14 proved to be a reliable option for distinguishing the basal phenotype, compared to the "gold standard" pair CK5/EGFR. Furthermore, P-cadherin was still able to recognize a large number of putative BLBC among the "unclassified" group (ER-/PR-/HER2-/CK5-/EGFR-).
P-cadherin, Vimentin and CK14 can recognize BLBC already identified in triple negative/ CK5 and/or EGFR+ tumors, and due to P-cadherin sensitivity for BLBC identification this marker can reliably recruit a large number of breast carcinomas with basal phenotype among immunohistochemistry triple negative/ CK5 and/or EGFR - pool of tumors. Although they need GEP validation, our results can introduce the idea of these markers as additional options in the daily workup of breast pathology laboratories to identify BLBC.
识别基底样乳腺癌(BLBC)的最合适的免疫组织化学标准是三阴性表型加上 CK5 和/或 EGFR 免疫反应,BLBC 是一种与预后不良相关的乳腺癌分子亚型。然而,已经提出了几种假定的基底标志物作为更准确地识别 BLBC 的替代方法。
评估了 462 例浸润性乳腺癌中 CK5、EGFR、P-钙黏蛋白、CK14、波形蛋白和 p63 的表达,以确定它们对 BLBC 识别的敏感性和特异性。
P-钙黏蛋白和 CK5 显示出更高的敏感性值,而 EGFR、波形蛋白和 CK14 是最特异的标志物。与“金标准”配对 CK5/EGFR 相比,CK5 与 P-钙黏蛋白、波形蛋白或 CK14 的组合被证明是区分基底表型的可靠选择。此外,P-钙黏蛋白仍然能够在“未分类”组(ER-/PR-/HER2-/CK5-/EGFR-)中识别大量假定的 BLBC。
P-钙黏蛋白、波形蛋白和 CK14 可以识别已经在三阴性/CK5 和/或 EGFR+肿瘤中识别的 BLBC,并且由于 P-钙黏蛋白对 BLBC 识别的敏感性,该标志物可以可靠地在免疫组织化学三阴性/CK5 和/或 EGFR-肿瘤池中招募大量具有基底表型的乳腺癌。尽管它们需要 GEP 验证,但我们的结果可以引入这些标志物作为识别 BLBC 的附加选择在乳腺病理实验室的日常工作中。